Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q2

9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥11.4bn2023-07-01 → 2023-12-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥11.2bn2022-07-01 → 2022-12-31Cons.Net sales
Operating income¥2.4bn2023-07-01 → 2023-12-31Cons.Operating income
Operating income¥2.2bn2022-07-01 → 2022-12-31Cons.Operating income
Ordinary income¥2.4bn2023-07-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.2bn2022-07-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥2.4bn2023-07-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.2bn2022-07-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.6bn2023-07-01 → 2023-12-31Cons.Profit loss
Net income¥1.4bn2022-07-01 → 2022-12-31Cons.Profit loss
Total assets¥29.6bnat 2023-12-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥7.7bnat 2023-12-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.0bnat 2023-12-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥19.6bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥11.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥10.3bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥10.0bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥8.2bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥8.4bnat 2022-06-30dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2023-07-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.7bn2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥518m2022-07-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥644m2023-07-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥304m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥120m2022-07-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥639m2023-07-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥812m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥600m2022-07-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥39.462023-07-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.342023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.192022-07-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio74.2%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.8%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-12-31−¥871m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-12-31−¥38m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥7.9bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥7.0bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2023-12-31¥871m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2023-12-31¥4.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2023-12-31¥1.0bn
—segment totalrevenue2023-07-01 → 2023-12-31¥12.3bn
—segment totalrevenue external2023-07-01 → 2023-12-31¥11.4bn
—segment totalrevenue intersegment2023-07-01 → 2023-12-31¥871m
—segment totalsegment profit2023-07-01 → 2023-12-31¥2.4bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-12-31−¥925m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-12-31¥22m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥8.1bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥7.2bn
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-12-31¥925m
jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥1.4bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-12-31¥4.0bn
jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-12-31¥761m
—segment totalrevenue2022-07-01 → 2022-12-31¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-12-31¥11.2bn
—segment totalrevenue intersegment2022-07-01 → 2022-12-31¥925m
—segment totalsegment profit2022-07-01 → 2022-12-31¥2.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Cost of salesPrior1YTDDuration7973282000JPY
Cost of salesCurrentYTDDuration7924332000JPY
Gross profitPrior1YTDDuration3193692000JPY
Gross profitCurrentYTDDuration3458609000JPY
Selling general and administrative expensesPrior1YTDDuration1033450000JPY
Selling general and administrative expensesCurrentYTDDuration1065308000JPY
Operating incomePrior1YTDDuration2160241000JPY
Operating incomeCurrentYTDDuration2393300000JPY
Interest and dividends income noiPrior1YTDDuration1841000JPY
Interest and dividends income noiCurrentYTDDuration1948000JPY
Foreign exchange gains noiPrior1YTDDuration3644000JPY
Foreign exchange gains noiCurrentYTDDuration12844000JPY
Commission fee noiPrior1YTDDuration9331000JPY
Commission fee noiCurrentYTDDuration3942000JPY
Compensation income noiPrior1YTDDuration7004000JPY
Compensation income noiCurrentYTDDuration640000JPY
Insurance income noiPrior1YTDDuration－JPY
Insurance income noiCurrentYTDDuration26533000JPY
Other noiPrior1YTDDuration2820000JPY
Other noiCurrentYTDDuration4269000JPY
Non operating incomePrior1YTDDuration24641000JPY
Non operating incomeCurrentYTDDuration50177000JPY
Interest expenses noePrior1YTDDuration3949000JPY
Interest expenses noeCurrentYTDDuration3359000JPY
Loss on valuation of securities noePrior1YTDDuration3071000JPY
Loss on valuation of securities noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration996000JPY
Other noeCurrentYTDDuration9000JPY
Non operating expensesPrior1YTDDuration8017000JPY
Non operating expensesCurrentYTDDuration3368000JPY
Ordinary incomePrior1YTDDuration2176866000JPY
Ordinary incomeCurrentYTDDuration2440109000JPY
Income before income taxesPrior1YTDDuration2176866000JPY
Income before income taxesCurrentYTDDuration2440109000JPY
Income taxes currentPrior1YTDDuration778653000JPY
Income taxes currentCurrentYTDDuration869987000JPY
Income taxes deferredPrior1YTDDuration3868000JPY
Income taxes deferredCurrentYTDDuration6816000JPY
Income taxesPrior1YTDDuration782522000JPY
Income taxesCurrentYTDDuration876803000JPY
Profit lossPrior1YTDDuration1394344000JPY
Profit lossCurrentYTDDuration1563306000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1394344000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1563306000JPY
Profit lossPrior1YTDDuration1394344000JPY
Profit lossCurrentYTDDuration1563306000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration175000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration15175000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration-66649000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-40951000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-07-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-07-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass